Tier 2 — strong

Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study

Sarah Egert, Anja Bosy-Westphal, Jasmin Seiberl, Claudia Kürbitz, Uta Settler, Sandra Plachta-Danielzik, Anika E Wagner, Jan Frank, Jürgen Schrezenmeir, Gerald Rimbach, Siegfried Wolffram, Manfred J Müller
The British journal of nutrition 2009 102(7):1065

Bibliography

PubMed
PMID 19402938
DOI
10.1017/S0007114509359127
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled crossover trial
ModelHuman intervention research
Sample93 adults with overweight or obesity and metabolic-syndrome traits
InterventionQuercetin 150 mg/day or placebo
Duration6 weeks per treatment; 5-week washout
EndpointsBlood pressure; Lipid measurements; Inflammatory measures

What the study showed, in plain terms

Published in 2009, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled crossover trial. Sample/model: 93 adults with overweight or obesity and metabolic-syndrome traits. The exposure or intervention was Quercetin 150 mg/day or placebo. Follow-up or treatment period: 6 weeks per treatment; 5-week washout.

Systolic pressure and oxidized LDL decreased modestly. HDL also decreased, while most lipid ratios and inflammatory markers were unchanged.

Short trial of mixed surrogate outcomes. APOE and monocyte analyses from this intervention are related reports, not new trial populations.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin and Blood Pressure: How Large Is the Effect?. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Systolic pressure and oxidized LDL decreased modestly.
  • HDL also decreased, while most lipid ratios and inflammatory markers were unchanged.
  • The recorded outcome domains were Blood pressure; Lipid measurements; Inflammatory measures.
  • The result applies to the tested exposure: Quercetin 150 mg/day or placebo; 6 weeks per treatment; 5-week washout.

What this study can and cannot tell us

  • Short trial of mixed surrogate outcomes. APOE and monocyte analyses from this intervention are related reports, not new trial populations.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype
Sarah Egert et al. · The Journal of nutrition · 2010
Tier 2
Effect of quercetin on paraoxonase 2 levels in RAW264.7 macrophages and in human monocytes--role of quercetin metabolism
Christine Boesch-Saadatmandi et al. · International journal of molecular sciences · 2009
Tier 2
Quercetin supplementation and its effect on human monocyte gene expression profiles in vivo
Inka Boomgaarden et al. · The British journal of nutrition · 2010
Tier 1
The effects of Quercetin supplementation on cardiometabolic outcomes: An umbrella review of meta-analyses of randomized controlled trials
Seyyed Mostafa Arabi et al. · Phytotherapy research : PTR · 2023
Tier 1
The Effects of Quercetin Supplementation on Blood Pressure - Meta-Analysis
Joanna Popiolek-Kalisz et al. · Current problems in cardiology · 2022

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology